YU41703A - Cikloheksil(alkil)propanolamini, njihovo dobijanje i farmaceutski preparati - Google Patents

Cikloheksil(alkil)propanolamini, njihovo dobijanje i farmaceutski preparati

Info

Publication number
YU41703A
YU41703A YU41703A YUP41703A YU41703A YU 41703 A YU41703 A YU 41703A YU 41703 A YU41703 A YU 41703A YU P41703 A YUP41703 A YU P41703A YU 41703 A YU41703 A YU 41703A
Authority
YU
Yugoslavia
Prior art keywords
agents
formula
compounds
pharmaceutical compositions
compositions containing
Prior art date
Application number
YU41703A
Other languages
English (en)
Inventor
Philippe R. Bovy
Roberto Cecchi
Gilles Courtemanche
Ambrogio Oliva
Nunzia Viviani
Tiziano Crocci
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to MEP-233/08A priority Critical patent/MEP23308A/xx
Publication of YU41703A publication Critical patent/YU41703A/sh
Publication of RS51571B publication Critical patent/RS51571B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ovaj pronalazak se odnosi na jedinjenja formule (I): gde: A je grupa formule (a) ili (b) gde: R predstavlja atom vodonika ili halogena, -S(O)z(C1-C4)alkil grupu, -NHSO2(C1-C4)alkil grupu, SO2NH(C1-C4)alkil grupu, -NHSO2fenil (C1-C4)alkil grupu ili-NHSO2fenil grupu, gde je dati fenil po potrebi supstituisan sa atomom halogena, sa (C1-C4)alkil grupom ili sa (C1-C4)alkoksi grupom; R1 predstavlja atom vodonika ili (C1-C4)alkil grupu, -CO(C1-C4)alkil grupu, fenil-(C1-C4)alkil grupu ili -CO-fenil grupu, gde je dati fenil po potrebi supstituisan atomom halogena ili (C1-C4)alkoksi grupom; R2 je atom vodonika, -SO2(C1-C4)alkil grupa, -SO2fenil-(C1-C4)alkil grupa ili -SO2fenil grupa; X pravi prsten od 5 do 8 atoma, gde je dati prsten zasicen ili nezasicen, po potrebi supstituisan sa jednom ili dve (C1-C4)alkil grupe i vezana jedna ili dve karboksilne grupe; n, m, i z su nezavisno 0, 1 ili 2; R3 predstavlja atom vodonika ili halogena, (C1-C6)alkil grupu, (C1-C4)alkoksi grupu, -COO(C1-C4)alkil grupu, -CO-(C1-C4)alkil grupu, -NHSO2(C1-C4)alkil, -NHSO2fenil-(C1-C4)alkil grupu, -NO2, -CN, -CONR4R5, -COOH, ili 4,5-dihidro-1-,3-oksazol-2-il ili 4,4-dimetil-4,5-dihidro-1,3-oksazol-2-il grupu; R4 i R5 predstavljaju, nezavisno, atom vodonika, fenil, (C1-C4)alkil grupu ili fenil-(C1-C4)alkil grupu; ili R4 i R5 zajedno sa azotom za koji su vezani, mogu obrazovati prsten sa 5 do 7 atoma, ukupno; i njihove soli ili solvati u farmaceutskim preparatima koji sadrze ova jedinjenja, na postupak njihovog dobijanja i na intermedijere u ovom postupku.
YU41703A 2000-11-30 2001-11-30 CYCLOHEXYL (ARYL) PROPANOLAMINES, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS RS51571B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-233/08A MEP23308A (en) 2000-11-30 2001-11-30 Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0015477A FR2817257B1 (fr) 2000-11-30 2000-11-30 Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant

Publications (2)

Publication Number Publication Date
YU41703A true YU41703A (sh) 2006-05-25
RS51571B RS51571B (en) 2011-08-31

Family

ID=8857054

Country Status (25)

Country Link
US (3) US7388031B2 (sh)
EP (1) EP1341753B1 (sh)
JP (1) JP4024149B2 (sh)
CN (2) CN1283622C (sh)
AR (1) AR031438A1 (sh)
AT (1) ATE374177T1 (sh)
AU (2) AU2207902A (sh)
BR (1) BR0115768A (sh)
CA (1) CA2429267C (sh)
CY (1) CY1106997T1 (sh)
CZ (1) CZ305140B6 (sh)
DE (1) DE60130676T2 (sh)
DK (1) DK1341753T3 (sh)
ES (1) ES2290201T3 (sh)
FR (1) FR2817257B1 (sh)
HK (1) HK1055945A1 (sh)
HU (1) HU229583B1 (sh)
ME (1) MEP23308A (sh)
MX (1) MXPA03004884A (sh)
PL (1) PL206695B1 (sh)
PT (1) PT1341753E (sh)
RS (1) RS51571B (sh)
SI (1) SI1341753T1 (sh)
SK (1) SK287551B6 (sh)
WO (1) WO2002044139A1 (sh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2817257B1 (fr) * 2000-11-30 2009-03-20 Sanofi Synthelabo Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
FR2840301B1 (fr) * 2002-05-29 2007-03-23 Sanofi Synthelabo Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique
FR2840304B1 (fr) * 2002-05-29 2007-05-18 Sanofi Synthelabo Derives d'oxophenyl-cyclohexyl-propanolamine, leur preparation et leur application en therapeutique
EP2011490A1 (en) * 2007-07-05 2009-01-07 Sanofi-Aventis Beta adrenergic receptor ligand derivatives for modulating apoptosis
FR2935141B1 (fr) * 2008-08-21 2010-10-08 Sanofi Aventis Procede de preparation de l'ester ethylique de l'acide 4-[trans-4-[(phenylmethyl)-amino]cyclohexyl]benzoique et de son sel hemifumarate
AU2009308708B2 (en) * 2008-10-31 2015-11-19 Medivation Technologies, Inc. Azepino [4, 5-b] indoles and methods of use
CN116143575B (zh) * 2023-04-21 2023-06-30 研峰(天津)科学技术应用研究有限公司 昆虫信息素原料3-环己基-1-丙炔合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4004028A (en) * 1975-08-06 1977-01-18 Smithkline Corporation Phenoxypropanolamines
ES2067541T3 (es) * 1988-06-03 1995-04-01 Lilly Co Eli Mejoras en antagonistas de la serotonina y relacionadas con ellos.
US5096908A (en) 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
US5258379A (en) 1990-05-04 1993-11-02 Eli Lilly And Company Method of inhibiting gastric acid secretion with n-arylpiperazines
US5158956A (en) 1990-05-04 1992-10-27 Eli Lilly And Company Method of inhibiting gastric acid secretion with benzodioxanes
US5340838A (en) 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IL107611A0 (en) 1992-11-18 1994-02-27 Smithkline Beecham Corp Steroid compounds and pharmaceutical compositions containing them
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
IL110857A0 (en) 1993-09-09 1994-11-28 Lilly Co Eli Cessation of tobacco use
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5776959A (en) 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
CN1202106A (zh) * 1995-09-21 1998-12-16 伊莱利利公司 选择性的β3肾上腺素能激动剂
EP0792649A1 (en) 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders
US5958429A (en) 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
US20020019440A1 (en) * 1996-11-05 2002-02-14 Virbac Sa Aryloxypropanolamine derivatives, method of preparation and applications thereof
FR2755439B1 (fr) 1996-11-05 1998-12-24 Virbac Sa Derives aryloxypropanolamines, leur procede de preparation et leurs applications
FR2758460B1 (fr) * 1997-01-21 1999-12-31 Sanofi Sa Utilisation des agonistes des recepteurs beta-3 adrenergiques pour la preparation de medicaments cicatrisants
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
FR2780057B1 (fr) * 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
JP2000086603A (ja) 1998-07-15 2000-03-28 Yoshitomi Pharmaceut Ind Ltd 桂皮酸アミド誘導体および３―フェニルプロピオン酸アミド誘導体
AU2400300A (en) 1998-12-30 2000-07-31 Eli Lilly And Company Solution phase synthesis of compounds including amine alcohol functionality
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US20020019940A1 (en) * 2000-06-16 2002-02-14 Matteson Craig S. Method and apparatus for assigning test and assessment instruments to users
AUPQ841300A0 (en) * 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
SK632003A3 (en) 2000-07-13 2003-06-03 Lilly Co Eli Beta3 adrenergic agonists
FR2817257B1 (fr) 2000-11-30 2009-03-20 Sanofi Synthelabo Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
FR2840304B1 (fr) * 2002-05-29 2007-05-18 Sanofi Synthelabo Derives d'oxophenyl-cyclohexyl-propanolamine, leur preparation et leur application en therapeutique
FR2840301B1 (fr) 2002-05-29 2007-03-23 Sanofi Synthelabo Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique
WO2004006849A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
WO2004019932A1 (en) 2002-08-30 2004-03-11 Pharmacia & Upjohn Company Method of preventing or treating atherosclerosis or restenosis
PL378295A1 (pl) 2003-02-24 2006-03-20 Arena Pharmaceuticals, Inc. Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu
JP2007528400A (ja) 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬

Also Published As

Publication number Publication date
EP1341753A1 (fr) 2003-09-10
US20040053916A1 (en) 2004-03-18
US20080261949A1 (en) 2008-10-23
US7419974B2 (en) 2008-09-02
ATE374177T1 (de) 2007-10-15
DE60130676D1 (de) 2007-11-08
HUP0400565A3 (en) 2004-08-30
CY1106997T1 (el) 2012-01-25
US7718646B2 (en) 2010-05-18
CA2429267C (fr) 2010-09-28
SK6522003A3 (en) 2003-11-04
ES2290201T3 (es) 2008-02-16
PT1341753E (pt) 2007-11-13
MXPA03004884A (es) 2004-05-04
EP1341753B1 (fr) 2007-09-26
SI1341753T1 (sl) 2007-12-31
HUP0400565A2 (hu) 2004-06-28
AR031438A1 (es) 2003-09-24
AU2002222079B2 (en) 2006-12-14
AU2207902A (en) 2002-06-11
CA2429267A1 (fr) 2002-06-06
MEP23308A (en) 2010-06-10
JP2004514708A (ja) 2004-05-20
CN1283622C (zh) 2006-11-08
JP4024149B2 (ja) 2007-12-19
FR2817257A1 (fr) 2002-05-31
BR0115768A (pt) 2003-12-30
PL206695B1 (pl) 2010-09-30
SK287551B6 (sk) 2011-01-04
HU229583B1 (en) 2014-02-28
CN1478074A (zh) 2004-02-25
CN1935787A (zh) 2007-03-28
CZ305140B6 (cs) 2015-05-20
PL364746A1 (en) 2004-12-13
CZ20031499A3 (cs) 2003-08-13
HK1055945A1 (en) 2004-01-30
US7388031B2 (en) 2008-06-17
DK1341753T3 (da) 2008-01-14
FR2817257B1 (fr) 2009-03-20
DE60130676T2 (de) 2008-07-17
RS51571B (en) 2011-08-31
US20070015745A1 (en) 2007-01-18
WO2002044139A1 (fr) 2002-06-06

Similar Documents

Publication Publication Date Title
GEP20074197B (en) 5ht2c receptor modulators
IS2833B (is) 1,5 Bensóþíósepín og notkun þeirra gegn fitublæði
HUT72436A (en) Process for the production of imidazopyridines and pharmaceutical compositions containing them and which are suitable for treating gastro-intestinal diseases
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
SE9902987D0 (sv) Novel compounds
SE0103836D0 (sv) Novel compounds
YU84603A (sh) Novi inhibitori tirozin kinaze
MXPA04000756A (es) Nuevos compuestos.
HK1048990A1 (en) Novel compounds.
HK1050899A1 (en) Pteridine compounds for the treatment of psoriasis
MX2021012904A (es) Moduladores de la via de respuesta al estres integrada.
AU2002363182A1 (en) Smad7 inhibitors for the treatment of cns diseases
YU41703A (sh) Cikloheksil(alkil)propanolamini, njihovo dobijanje i farmaceutski preparati
GB0104050D0 (en) Chemical compounds
PL1778622T3 (pl) Para-alkilo-podstawione amidy kwasu N-(hydroksy-3-metoksybenzylo)-cynamonowego i ich zastosowanie do wytwarzania środków leczniczych
HK1073245A1 (en) Use of trifluoroacetyl alkyl-substituted phenyl derivatives, phenol derivatives, and benzoyl derivatives in the treatment and/or prophylaxis of obesity and accompanying diseases and/or secondary diseases
IL107654A0 (en) Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists certain such novel compounds their preparation and pharmaceutical compositions containing them
EP1439841A4 (en) ANDROGEN RECEPTOR MODULATORS AND USE METHOD THEREFOR
MXPA04005809A (es) Inhibidores de proteinas quinasas.
ATE207910T1 (de) Anti-helicobacter ester- oder carbamatderivate von azolonen
CZ83795A3 (en) 4-quinolinyl derivatives per se for use in medicine, process of their preparation, pharmaceutical compositions based thereon process of their preparation
ZA200300218B (en) Novel N-(2-phenyl-3-aminopropyl)naphtamides.
ATE553078T1 (de) Neues benzoylguanidinsalz
IL156639A0 (en) Phenethanolamine derivatives, methods for their preparation and pharmaceutical compositions containing them